Pradaxa Antidote Receives Full FDA Approval for Reversal of Bleeding Problems
The FDA has granted full approval for the Pradaxa reversal agent, Praxbind, following positive results from phase III clinical trials.
The FDA has granted full approval for the Pradaxa reversal agent, Praxbind, following positive results from phase III clinical trials.
The reversal agent for Pradaxa, Praxbind, appears to be working as it should and quickly cancelling the drug's blood thinning effects in nearly all patients, according to the findings of…
The findings of a new study indicate that combining the blood thinner Pradaxa with the cholesterol drugs Zocor, Mevacor and Altoprev can significantly increase the risk of serious bleeding events…
A reversal agent for the blood thinner Pradaxa is now available nationwide after thousands of bleeding events and lawsuits.
The FDA has approved a reversal agent for the blood thinner Pradaxa called Praxbind, which is supposed to stop the drug's blood thinning effects in patients suffering a bleeding emergency.
Pradaxa is close to having a reversal agent approved in Europe, which may give it an edge over other blood thinner competitors.